A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2019
Price : $35 *
At a glance
- Drugs Degarelix (Primary) ; Ipilimumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 05 Jun 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 05 Jun 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 31 Aug 2018 Biomarkers information updated